Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DNA
DNA logo

DNA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Ginkgo Bioworks Holdings Inc (DNA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.170
1 Day change
7.25%
52 Week Range
17.580
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Ginkgo Bioworks Holdings Inc (DNA) is not a strong buy for a beginner, long-term investor at this time. The lack of positive trading signals, insider selling, bearish technical indicators, and absence of recent news or financial data make it a less compelling investment opportunity. A hold strategy is recommended until more favorable conditions emerge.

Technical Analysis

The MACD histogram is positive and expanding, which is a bullish signal. However, the RSI is in the neutral zone at 72.796, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 8.969, R2: 9.341), suggesting limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
8

Positive Catalysts

  • The MACD histogram is positive and expanding, indicating some bullish momentum. The stock has a 10.35% chance of increasing in the next month.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 74248.78% increase in selling activity over the last month. Moving averages are bearish, and there are no significant hedge fund trading trends. No recent news or financial data is available to support a bullish case.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available.

Wall Street analysts forecast DNA stock price to rise
1 Analyst Rating
Wall Street analysts forecast DNA stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.550
sliders
Low
12
Averages
12
High
12
Current: 8.550
sliders
Low
12
Averages
12
High
12
BTIG
Mark Massaro
Sell
downgrade
$9 -> $5
AI Analysis
2026-03-12
Reason
BTIG
Mark Massaro
Price Target
$9 -> $5
AI Analysis
2026-03-12
downgrade
Sell
Reason
BTIG analyst Mark Massaro lowered the firm's price target on Ginkgo Bioworks to $5 from $9 and keeps a Sell rating on the shares. The company announced the divestiture of its biosecurity business, which limits its guidance to cash burn, the analyst tells investors in a research note. BTIG adds, however, that it is now looking for greater visibility into Ginkgo's progress to build out and monetize autonomous labs.
TD Cowen
Buy
downgrade
$142 -> $12
2026-01-08
Reason
TD Cowen
Price Target
$142 -> $12
2026-01-08
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Ginkgo Bioworks to $12 from $142 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DNA
Unlock Now

People Also Watch